A study supported by Blue Earth Diagnostics showed that physicians can be trained to successfully interpret Axumin PET scan images of patients with suspected recurrence of prostate cancer. {read more here}

PET/CT is superior to contrast-enhanced CT when it comes to predicting both progression-free and disease-specific survival in patients with metastatic breast cancer, according to a study published online May 1 in the European Journal of Nuclear Medicine and Molecular Imaging. {read more here}

Researchers have combined PET scans with a newly developed probe to help determine the efficacy of cancer treatments, according to a study published April 30 in Cancer Research. {read more here}

Brain cancers are difficult to treat, and it can be hard to predict whether a therapy will be effective. When the patient is a child, it’s even more important to predict the potential effectiveness of a drug before beginning treatment. In this first ever molecular drug-imaging study in children, researchers in The Netherlands used whole-body positron emission tomography/computed tomography (PET/CT) scans to determine whether bevacizumab (Avastin) treatment of diffuse intrinsic pontine glioma (DIPG) in children is likely to be effective. The study is featured in the May 2017 issue of The Journal of Nuclear Medicine. {read more here}